1. A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis. (19th June 2015) Authors: Papp, K.; Pariser, D.; Catlin, M.; Wierz, G.; Ball, G.; Akinlade, B.; Zeiher, B.; Krueger, J.G. Journal: British journal of dermatology Issue: Volume 173:Number 3(2015:Sep.) Page Start: 767 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis. (19th June 2015) Authors: Papp, K.; Pariser, D.; Catlin, M.; Wierz, G.; Ball, G.; Akinlade, B.; Zeiher, B.; Krueger, J.G. Journal: British journal of dermatology Issue: Volume 173:Number 3(2015:Sep.) Page Start: 767 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis. (1st September 2015) Authors: Papp, K.; Pariser, D.; Catlin, M.; Wierz, G.; Ball, G.; Akinlade, B.; Zeiher, B.; Krueger, J.G. Journal: British journal of dermatology Issue: Volume 173:Number 3(2015:Sep.) Page Start: 767 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. ASN002 demonstrates efficacy and improves inflammation in AD. (1st October 2019) Authors: Bissonnette, R.; Maari, C.; Forman, S.; Bhatia, N.; Lee, M.; Fowler, J.; Tyring, S.; Pariser, D.; Sofen, H.; Dhawan, S.; Zook, M.; Zammit, D.J.; Usansky, H.; Denis, L.; Rao, N.; Song, T.; Pavel, A.B.; Guttman‐Yassky, E. Journal: British journal of dermatology Issue: Volume 181:Number 4(2019) Page Start: e102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. ASN002 证明有疗效并可改善AD 炎症. (1st October 2019) Authors: Bissonnette, R.; Maari, C.; Forman, S.; Bhatia, N.; Lee, M.; Fowler, J.; Tyring, S.; Pariser, D.; Sofen, H.; Dhawan, S.; Zook, M.; Zammit, D.J.; Usansky, H.; Denis, L.; Rao, N.; Song, T.; Pavel, A.B.; Guttman‐Yassky, E. Journal: British journal of dermatology Issue: Volume 181:Number 4(2019) Page Start: e113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States. (11th October 2015) Authors: Kimball, A.B.; Schenfeld, J.; Accortt, N.A.; Anthony, M.S.; Rothman, K.J.; Pariser, D. Journal: British journal of dermatology Issue: Volume 173:Number 5(2015:Nov.) Page Start: 1183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States. (1st November 2015) Authors: Kimball, A.B.; Schenfeld, J.; Accortt, N.A.; Anthony, M.S.; Rothman, K.J.; Pariser, D. Journal: British journal of dermatology Issue: Volume 173:Number 5(2015:Nov.) Page Start: 1183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Continued treatment with secukinumab is associated with high retention or regain of response. (17th July 2019) Authors: Augustin, M.; Thaci, D.; Eyerich, K.; Pinter, A.; Radtke, M.; Lauffer, F.; Mrowietz, U.; Gerdes, S.; Pariser, D.; Lebwohl, M.; Sieder, C.; Melzer, N.; Reich, K. Journal: British journal of dermatology Issue: Volume 182:Number 1(2020) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Continued treatment with secukinumab is associated with high retention or regain of response. (1st January 2020) Authors: Augustin, M.; Thaci, D.; Eyerich, K.; Pinter, A.; Radtke, M.; Lauffer, F.; Mrowietz, U.; Gerdes, S.; Pariser, D.; Lebwohl, M.; Sieder, C.; Melzer, N.; Reich, K. Journal: British journal of dermatology Issue: Volume 182:Number 1(2020) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Correlation of psoriasis activity with socioeconomic status: cross‐sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). (1st October 2018) Authors: Kimball, A.B.; Augustin, M.; Gordon, K.B.; Krueger, G.G.; Pariser, D.; Fakharzadeh, S.; Goyal, K.; Calabro, S.; Lee, S.; Lin, R.; Li, N.; Srivastava, B.; Guenther, L. Journal: British journal of dermatology Issue: Volume 179:Number 4(2018) Page Start: 984 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗